ConductScience.org, home

Paper41335261

Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application.

Zhang Y and 7 others. Mol Biol Rep, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application. Papers, record 41335261. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41335261

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application.
PubMed
Journal
Mol Biol Rep
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-11-05
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhang YYao
2Lei YYuting
3Huang YYanzhao
4Gao YYan
5Liu RRong
6Guo KKaiyun
7Zhao CChunlian
8Lei MMing

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Multiple MyelomaMajor topic
Tumor MicroenvironmentMajor topic
ImmunotherapyMajor topic
Humans
Killer Cells, Natural
T-Lymphocytes, Regulatory
Dendritic Cells
Antibodies, Bispecific
Myeloid-Derived Suppressor Cells
Animals

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
No. 2022JJ40003Natural Science Foundation for Youth of Hunan ProvincePubMed
No.2024JJ7018Natural Science Foundation of Hunan ProvincePubMed
No.2023YD30Changde Science and Technology BoardPubMed

Source PubMed

Download CSV of grants

References97

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116150935Dysfunctional T regulatory cells in multiple myeloma.Blood2006https://conductscience.org/library/papers/16150935PubMed
238424196Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine.Nat Rev Clin Oncol2024https://conductscience.org/library/papers/38424196PubMed
338783333BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.J Nanobiotechnology2024https://conductscience.org/library/papers/38783333PubMed
429359507Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.Immunol Cell Biol2018https://conductscience.org/library/papers/29359507PubMed
534459681Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.Ann Med2021https://conductscience.org/library/papers/34459681PubMed
634175021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet2021https://conductscience.org/library/papers/34175021PubMed
739820043A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast.Sci Rep2025https://conductscience.org/library/papers/39820043PubMed
834072068CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.Cancers (Basel)2021https://conductscience.org/library/papers/34072068PubMed
922804669Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.Br J Haematol2012https://conductscience.org/library/papers/22804669PubMed
1038466644Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma.Clin Cancer Res2024https://conductscience.org/library/papers/38466644PubMed
1139855377Regulation of PD-L1 glycosylation and advances in cancer immunotherapy.Cancer Lett2025https://conductscience.org/library/papers/39855377PubMed
1239261906Updates on CAR T cell therapy in multiple myeloma.Biomark Res2024https://conductscience.org/library/papers/39261906PubMed
1335661166Teclistamab in Relapsed or Refractory Multiple Myeloma.N Engl J Med2022https://conductscience.org/library/papers/35661166PubMed
1427269947Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.J Clin Oncol2016https://conductscience.org/library/papers/27269947PubMed
1523321256Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.Blood2013https://conductscience.org/library/papers/23321256PubMed
1637883186BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions.J Clin Invest2024https://conductscience.org/library/papers/37883186PubMed
1738242888Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.Nat Commun2024https://conductscience.org/library/papers/38242888PubMed
1838052709Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.Clin Lymphoma Myeloma Leuk2024https://conductscience.org/library/papers/38052709PubMed
1936413710Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.J Clin Oncol2023https://conductscience.org/library/papers/36413710PubMed
2037501530T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.Curr Opin Oncol2023https://conductscience.org/library/papers/37501530PubMed

See all 97 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
42142763Nanoparticle-Based delivery of proteasome inhibitors for glioblastoma Therapy: Strategies to overcome Blood-Brain barrier and therapeutic resistance.Biochem Pharmacol2026https://conductscience.org/library/papers/42142763

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41335261

GET https://conductscience.org/api/papers/v1/41335261/references?page=2